TMCnet News
PixarBio Co-Founder and MIT Professor Dr. Robert S. Langer to Discuss the Evolution of NeuroRelease, a Non-Opiate and Non-Addictive Morphine Replacement Tonight Thursday October 13, 2016 at 8:00PMPixarBio Corporation, inventors of NeuroRelease™, a novel morphine replacement, non-opiate/opioid, non-addictive pain treatment with expected US FDA approval in late 2018, is pleased to announce MIT (News - Alert) Professor and PixarBio co-founder Dr. Robert S. Langer, or "Bob Langer" will be hosting a WebEx meeting tonight, Thursday October 13, 2016 at 8:00PM EST. The focus of the WebEx session will be the evolution of NeuroRelease and will feature NeuroRelease co-inventor Dr. Robert S. Langer or "Bob Langer" for comments on the company's revolutionary pain treatment. To join the by WebEx session please email [email protected] The acquisition of BMP Holdings will be finalized on Saturday October 22, 2016 and public trading of the new PixarBio Corporation will begin on Monday October 24, 2016.
The NeuroRelease™ Platform: Non-Addictive and Non-opiate
Treatment of Pain Major Benefits of NeuroRelease™
Therefore, patients will maintain two-point discriminate touch, control of their locomotion nerve fibers so they control voluntary movement to enter rehabilitation quickly with a non-addctive morphine replacement. PixarBio's NeuroRelease™ pain platform also includes 4-8 hour, 3-day, 7-day, 14-day and 90-Day pain treatments all have expected FDA approvals in 2020. NeuroRelease™ is biodegradable, and it's non-toxic so NeuroRelease™ can be re-injected to extend treatment timelines. PixarBio Corporation was awarded the Boston Business Journal's "2016 Best Places to Work". The award recognizes PixarBio as one of the region's best firms, offering the greatest professional opportunities and work environments to innovate.
About PixarBio Corporation
Safe Harbor Statement Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of Biotech and medical device industry regulation and health care legislation in the United States and internationally; global trends on cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; PixarBio's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of PixarBio's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. PixarBio Corp undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be obtained through PixarBio's Corp HQ at 200 Boston Ave, Suite 1875 in Medford, MA 02155. PixarBio Corp is a private corporation. View source version on businesswire.com: http://www.businesswire.com/news/home/20161013006027/en/ |